Short answer
BridgeBio Oncology Therapeutics Inc (BBOT) filed an 8-K current report with the SEC on November 10, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Press release announces BBOT financial results for quarter ended September 30, 2026.
BridgeBio Oncology Therapeutics Inc 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Press release announces BBOT financial results for quarter ended September 30, 2026
- Exhibit 99.1 contains the detailed quarterly results and management commentary
- Investors should review the exhibit for revenue, cash position, operating expenses, and pipeline updates
Item EX-99.1 · Exhibit EX-99.1
- BBO-8520 plus pembrolizumab achieved 75% ORR at 500 mg QD and 53% across doses in 2L+ KRAS G12C inhibitor-experienced NSCLC
- BBO-8520 monotherapy delivered 63% ORR and 100% DCR in 41 inhibitor-naïve NSCLC patients, supporting differentiated efficacy potential
- Combination cohorts for BBO-11818 and BBO-10203 are enrolling in KRAS-mutant CRC and PDAC, with monotherapy updates expected in Q4 2026
- Cash, equivalents and marketable securities totaled $315.3 million, with management projecting funding into 2029
- Nine-month net loss widened to $132.7 million from $95.2 million, while R&D expense rose to $118.6 million from $83.1 million
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other BridgeBio Oncology Therapeutics Inc 8-K filings
Get the next BBOT 8-K as it lands
Follow BBOT for push alerts, or ask the research agent what this filing means.